Doxorubicin Hydrochloride Injection, USP

Signal word

DANGER. GHS Class: Respiratory sensitisation. Category 1. Carcinogenicity. Category 1A. Germ cell mutagenicity. Category 2. Reproductive toxicity. Category 2. Skin Sensitization. Category 1. Reproductive toxicity. Effects on or via lactation.

Hazard statements

May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause cancer. Suspected of causing genetic defects. Suspected of damaging fertility or the unborn child. May cause an allergic skin reaction. May cause harm to breast-fed children.

Precautionary statements

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapours/spray. Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory protection. IF ON SKIN: Wash with plenty of water. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. IF exposed or concerned: Get medical advice/attention. Specific treatment (see ... on this label). If skin irritation or rash occurs: Get medical advice/attention. If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician. Take off contaminated clothing and wash it before reuse. Store locked up. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations. Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Principle Routes of Exposure

Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential health effects

Eye: Contact with eyes may cause irritation. Signs/Symptoms: Potential adverse reactions from prescribed doses are described in the package insert and include: acute and delayed cardiotoxicity, myelosuppression, secondary leukemia, hepatic impairment, nausea, vomiting, mucositis, ulceration and necrosis of the colon, hypersensitivity, peripheral neurotoxicity, alopecia, hyperpigmentation of nail beds and dermal creases, rash, itching and photosensitivity. The symptoms and signs of overdosage include enhanced toxic effects of mucositis, leukopenia, and thrombocytopenia. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Individuals with hypersensitivity to doxorubicin, any of its excipients, or other anthracyclines or Conditions: anthracenediones. Also, individuals with cardiovascular disease, hepatic, renal, and bone marrow impairment.